S.C. Ropharma (BVB:RPH) Full Year 2024 Results
Key Financial Results
- Revenue: RON1.33b (up 19% from FY 2023).
- Net loss: RON1.73m (down by 122% from RON7.72m profit in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
S.C. Ropharma shares are down 5.7% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 3 warning signs for S.C. Ropharma (2 are significant) you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if S.C. Ropharma might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.